VIDEO: EYP-1901 shows maintenance of visual acuity, reduced treatment burden at 12 months
Click Here to Manage Email Alerts
In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, of Retina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.
The study, the largest intravitreal tyrosine kinase inhibition trial to date, is investigating two doses of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet age-related macular degeneration vs. aflibercept 2 mg. Overall, a single injection of EYP-1901 demonstrated maintenance of visual acuity and reduced treatment burden, according to Eichenbaum.
“These results are encouraging,” he said. “They do imply that tyrosine kinase inhibition with vorolanib reduces the patient’s need for ongoing injections in an active treatment-experienced population, and these results are informing us to move on to the phase 3 trials.”
Collapse
Eichenbaum DA, et al. 12-month results from the DAVIO 2 trial: A phase 2, multicenter study of a single injection of EYP-1901 (vorolanib intravitreal insert) vs aflibercept for previously-treated patients with wet age-related macular degeneration. Presented at: Retina Society meeting; Sept. 11-15, 2024; Lisbon, Portugal.
Read more about
Click Here to Manage Email Alerts